Stockscreener 앱 받기
0.615
5.83%
-0.0329
전일 마감가:
$0.6479
열려 있는:
$0.6195
하루 거래량:
1.31M
Relative Volume:
0.08
시가총액:
$14.35M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.2431
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
-27.72%
1개월 성능:
-22.68%
6개월 성능:
-55.14%
1년 성능:
-66.11%
1일 변동 폭
$0.58
$0.645
1주일 범위
$0.58
$0.8696
52주 변동 폭
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.6101 | 14.35M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.20 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.98 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | D. Boral Capital | Buy |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock Split | PSTV Stock News - GuruFocus
PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com
Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News
Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com
Plus Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - The Houston 100
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Plus Therapeutics adds Kyle Guse to its Board of Directors By Investing.com - Investing.com South Africa
Plus Therapeutics Inc (PSTV) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Plus Therapeutics adds Kyle Guse to its Board of Directors - Investing.com
Plus Therapeutics (PSTV) Welcomes Kyle Guse to Board as Audit Ch - GuruFocus
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors - marketscreener.com
Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World
Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World
Plus Therapeutics Appoints Kyle Guse to Board - MSN
Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada
Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus
Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus
Plus Therapeutics reports progress in CNS cancer treatment - Investing.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire
New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan
Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus
Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister
Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks
Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com
PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):